1282 related articles for article (PubMed ID: 24189462)
1. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
2. Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project.
Abrahamsson B; McAllister M; Augustijns P; Zane P; Butler J; Holm R; Langguth P; Lindahl A; Müllertz A; Pepin X; Rostami-Hodjegan A; Sjögren E; Berntsson M; Lennernäs H
Eur J Pharm Biopharm; 2020 Jul; 152():236-247. PubMed ID: 32446960
[TBL] [Abstract][Full Text] [Related]
3. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
4. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
5. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
6. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.
Lennernäs H; Lindahl A; Van Peer A; Ollier C; Flanagan T; Lionberger R; Nordmark A; Yamashita S; Yu L; Amidon GL; Fischer V; Sjögren E; Zane P; McAllister M; Abrahamsson B
Mol Pharm; 2017 Apr; 14(4):1307-1314. PubMed ID: 28195732
[TBL] [Abstract][Full Text] [Related]
8. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
[TBL] [Abstract][Full Text] [Related]
9. IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.
Margolskee A; Darwich AS; Pepin X; Pathak SM; Bolger MB; Aarons L; Rostami-Hodjegan A; Angstenberger J; Graf F; Laplanche L; Müller T; Carlert S; Daga P; Murphy D; Tannergren C; Yasin M; Greschat-Schade S; Mück W; Muenster U; van der Mey D; Frank KJ; Lloyd R; Adriaenssen L; Bevernage J; De Zwart L; Swerts D; Tistaert C; Van Den Bergh A; Van Peer A; Beato S; Nguyen-Trung AT; Bennett J; McAllister M; Wong M; Zane P; Ollier C; Vicat P; Kolhmann M; Marker A; Brun P; Mazuir F; Beilles S; Venczel M; Boulenc X; Loos P; Lennernäs H; Abrahamsson B
Eur J Pharm Sci; 2017 Jan; 96():598-609. PubMed ID: 27671970
[TBL] [Abstract][Full Text] [Related]
10. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
11. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
[TBL] [Abstract][Full Text] [Related]
12. In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration.
Butler J; Hens B; Vertzoni M; Brouwers J; Berben P; Dressman J; Andreas CJ; Schaefer KJ; Mann J; McAllister M; Jamei M; Kostewicz E; Kesisoglou F; Langguth P; Minekus M; Müllertz A; Schilderink R; Koziolek M; Jedamzik P; Weitschies W; Reppas C; Augustijns P
Eur J Pharm Biopharm; 2019 Mar; 136():70-83. PubMed ID: 30579851
[TBL] [Abstract][Full Text] [Related]
13. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
14. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development.
Lennernäs H
Mol Pharm; 2014 Jan; 11(1):12-23. PubMed ID: 24206063
[TBL] [Abstract][Full Text] [Related]
15. Paediatric oral biopharmaceutics: key considerations and current challenges.
Batchelor HK; Fotaki N; Klein S
Adv Drug Deliv Rev; 2014 Jun; 73():102-26. PubMed ID: 24189013
[TBL] [Abstract][Full Text] [Related]
16. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
17. In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.
Sjögren E; Abrahamsson B; Augustijns P; Becker D; Bolger MB; Brewster M; Brouwers J; Flanagan T; Harwood M; Heinen C; Holm R; Juretschke HP; Kubbinga M; Lindahl A; Lukacova V; Münster U; Neuhoff S; Nguyen MA; Peer Av; Reppas C; Hodjegan AR; Tannergren C; Weitschies W; Wilson C; Zane P; Lennernäs H; Langguth P
Eur J Pharm Sci; 2014 Jun; 57():99-151. PubMed ID: 24637348
[TBL] [Abstract][Full Text] [Related]
18. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.
Darwich AS; Margolskee A; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
Eur J Pharm Sci; 2017 Jan; 96():626-642. PubMed ID: 27693299
[TBL] [Abstract][Full Text] [Related]
19. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
20. Introduction to the OrBiTo decision tree to select the most appropriate in vitro methodology for release testing of solid oral dosage forms during development.
Andreas CJ; Rosenberger J; Butler J; Augustijns P; McAllister M; Abrahamsson B; Dressman J
Eur J Pharm Biopharm; 2018 Sep; 130():207-213. PubMed ID: 30064698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
